Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -2030.10% is in line with its 5-year average of -1919.72%, near the high end of its 5-year range (-28670.14%–-209.49%).
86.04% above its 12-month average of -14543.90%.
Reported quarterly EBITDA margin; no daily interpolation. Q4 FY2023 (2023-03-31): -417.66%.
EBITDA MARGIN
-2030.10%
EBITDA MARGIN AVG TTM
-14543.90%
EBITDA MARGIN AVG 3Y
-6829.37%
EBITDA MARGIN AVG 5Y
-1919.72%
EBITDA MARGIN AVG 10Y
-917.22%
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+86.04%
CURRENT VS 3Y AVG
+70.27%
CURRENT VS 5Y AVG
-5.75%
CURRENT VS 10Y AVG
-121.33%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Aethlon Medical, Inc.
Market Cap
$3.44M
EBITDA Margin
-2030.10%
TTM Avg
-14543.90%
3Y Avg
-6829.37%
5Y Avg
-1919.72%
Market Cap
$3.47M
EBITDA Margin
-437.97%
TTM Avg
-452.41%
3Y Avg
-479.95%
5Y Avg
-376.71%
Market Cap
$3.48M
EBITDA Margin
-334.54%
TTM Avg
-323.48%
3Y Avg
-700.81%
5Y Avg
-1335.84%
Market Cap
$3.37M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.13M
EBITDA Margin
-22711.52%
TTM Avg
-15924.10%
3Y Avg
-12940.13%
5Y Avg
-12940.13%
Market Cap
$3.09M
EBITDA Margin
-4291.67%
TTM Avg
-3563.06%
3Y Avg
-8274.29%
5Y Avg
-15578.54%
Market Cap
$3.94M
EBITDA Margin
-890.82%
TTM Avg
-527.81%
3Y Avg
-554.45%
5Y Avg
-445.87%
Market Cap
$4.18M
EBITDA Margin
-1456.00%
TTM Avg
-1456.00%
3Y Avg
-1456.00%
5Y Avg
-1456.00%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aethlon Medical, Inc. (AEMD) | $3.44M | -2030.10% | -14543.90% | -6829.37% | -1919.72% |
| IceCure Medical Ltd (ICCM)vs › | $3.47M | -437.97% | -452.41% | -479.95% | -376.71% |
| Evogene Ltd. (EVGN)vs › | $3.48M | -334.54% | -323.48% | -700.81% | -1335.84% |
| Cadrenal Therapeutics, Inc. Common Stock (CVKD)vs › | $3.37M | N/A | N/A | N/A | N/A |
| Eocene Ltd. (EOCN)vs › | $3.59M | N/A | N/A | N/A | N/A |
| Adagio Medical Holdings, Inc. (ADGM)vs › | $3.13M | -22711.52% | -15924.10% | -12940.13% | -12940.13% |
| BioRestorative Therapies, Inc. (BRTX)vs › | $3.09M | -4291.67% | -3563.06% | -8274.29% | -15578.54% |
| Aptevo Therapeutics Inc. (APVO)vs › | $3.94M | -890.82% | -527.81% | -554.45% | -445.87% |
| GRI Bio, Inc. (GRI)vs › | $4.18M | -1456.00% | -1456.00% | -1456.00% | -1456.00% |
| iSpecimen Inc. (ISPC)vs › | $2.64M | -375.69% | -244.00% | -166.51% | -121.60% |
Gross Margin
0.0%
EBITDA Margin
-2030.1%
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2023-03-31 | -417.66% |
| 2022-03-31 | -28670.14% |
| 2021-12-31 | -14665.38% |
| 2021-09-30 | -1469.91% |
| 2021-06-30 | -1581.30% |
| 2021-03-31 | -6582.57% |
| 2020-12-31 | -389.47% |
| 2020-03-31 | -858.52% |
| 2019-12-31 | -209.49% |
| 2019-06-30 | -5211.07% |
| 2019-03-31 | -1981.33% |
| 2018-06-30 | -727.75% |
| 2018-03-31 | -1687.89% |
| 2017-12-31 | -1543.68% |
| 2016-09-30 | -572.12% |
| 2016-06-30 | -24202.42% |
| 2016-03-31 | -525.77% |
| 2015-12-31 | -356.80% |
| 2015-09-30 | -591.75% |
| 2015-06-30 | -561.36% |
| 2015-03-31 | -565.76% |
| 2014-12-31 | -3223.25% |
| 2014-09-30 | -123.50% |
| 2014-06-30 | -2266.57% |
| 2014-03-31 | -113.59% |
| 2013-12-31 | -1602.04% |
| 2013-09-30 | -35.31% |
| 2013-06-30 | -399.58% |
| 2013-03-31 | -208.85% |
| 2012-12-31 | -447.59% |
| 2012-09-30 | -199.26% |
| 2012-06-30 | -455.95% |
| 2012-03-31 | -212.84% |
| 2011-12-31 | -35.17% |
| 2011-03-31 | 3.95% |
